上海醫藥(601607.SH)2019年度扣非淨利潤升30.49%至34.61億元 研發投入達15.09億元
格隆匯3月27日丨上海醫藥(601607.SH)披露2019年年度報告，實現營業收入1865.66億元，同比增長17.27%；歸屬於上市公司股東的淨利潤40.81億元，同比增長5.15%；歸屬於上市公司股東的扣除非經常性損益的淨利潤34.61億元，同比上升30.49%；擬每10股派發現金紅利4.4元(含税)。
公司經營性現金流淨流入60.22億元，同比增長92.09%，其中醫藥工業實現經營性現金淨流入34.56億元，醫藥商業實現經營性現金淨流入30.65億元。
報告期內，醫藥工業實現收入234.90億元，同比增長20.70%，增速連續11個季度超過20%；醫藥商業實現收入1630.76億元，同比增長16.80%。
盈利方面，醫藥工業主營業務貢獻利潤20.75億元，同比增長24.50%；醫藥商業主營業務貢獻利潤22.25億元，同比增長26.75%，各項主營業務均保持快速增長。參股企業貢獻利潤7.65億元，同比增加18.14%。
公司是一家全產業鏈佈局的醫藥集團公司，製藥能力領先，商業網絡廣佈，業務協同效應突出，風險抵禦能力顯著。過去幾年，上海醫藥定戰略、建機制、補短板、強基礎，推進以“創新發展、集約化發展、國際化發展、融產結合發展”為核心的轉型發展戰略，再次駛入業績增長的快車道。
通過持續加大研發創新投入，創新引入市場化機制，推進開放多元的創新模式，建設國內外創新平台，加快創新對外合作，上海醫藥的創新發展在多個維度取得了長足進步。
報告期內，公司研發投入達到15.09億元，其中研發費用達到13.50億元，同比增長27.22%。
創新藥方面，公司已有15個產品(16個適應症)的項目處於臨牀研究及臨牀試驗申請階段。其中，自主研發管線中的SPH3127與雷騰舒(羥基雷公藤內酯醇片)類風關適應症於報告期內正式啟動了臨牀II期試驗，雷騰舒抗艾滋病適應症臨牀II期試驗完成首例受試者入組；2019年11月，公司還通過license-in方式引入了first-in-class腦卒中新藥LT3001，BD管線進一步擴充。仿製藥方面，鹽酸二甲雙胍片、頭孢氨苄膠囊、布洛芬緩釋膠囊、馬來酸依那普利片於報告期內通過了一致性評價，截至報告期末已有8個品種(9個品規)通過一致性評價，居於全國前列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
